|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immune Activation in Patients With Irritable Bowel Syndrome显示文摘 | Tobias Liebregts Birgit Adam Christoph Bredack Alexander R?th Susanne Heinzel Sue Lester Sarah Downie–Doyle Eric Smith Paul Drew Nicholas J. Talley Gerald Holtmann | 2007 | Gastroenterology2007，，3： | 1 |
| 2 | A placebo-controlled trial of itopride in functional dyspepsia 显示文摘 | Hohmann G Talley N J Liebregts T | 2006 | N Engl J Med2006，354，8： | 1 |
| 3 | Maintaining remission of ulcerative colitis with the probiotic Eseherichia Coli Nissle 1917 is as effective as with standard mesalazine显示文摘 | Adam B Liebregts T Holtmann G | 2006 | Z Gas- troenterol2006，44，3： | 1 |
| 4 | Host immune response deter- mines visceral hypeialgesia in a rat model of post-inflammatory irrt- able bowel syndrome 显示文摘 | Adam B Tsopelas C Liebregts T | 2013 | J Gastroenterol2013，11，6： | 1 |
| 5 | Mechanisms of disease : genetics of functional gastrointestinal disorders-searching the genes that matter显示文摘 | Adam B Liebregts T Hohmann G | 2007 | Nat Clin Pract Gastroenterol Hep- atol2007，4，2： | 1 |
| 6 | The link between meal related s ympotoms and cytokine release in patients with func-tional dyspepsia显示文摘 | Liebregts T Adam B Bredack C | 2006 | Gastroenterology2006，130，2： | 1 |
| 7 | Distribution and identify of biotypes of Bemisia tabaci (Gennadius) (Hemiptera: Aleyrodidae) in member countries of tbe Secretariat of tbe Pacific Community显示文摘 | De Barro P J Liebregts W Carver M | 1998 | Anstra J Entomal1998，37，： | 1 |
| 8 | A placebo-controlled trim of itopride in functional dyspepsia显示文摘 | HOLTMANN G TALLEY NJ LIEBREGTS T et ol | 2006 | N Engl J Med2006，354，8： | 1 |
| 9 | A Placebo-Controlled Trial of Itopride in Functional Dyspepsia 显示文摘 | Holtmann G Talley NJ Liebregts T | 2006 | N Engl J Med2006，354，8： | 1 |
| 10 | Small bowel homing T cells areassociated with symptoms and delayed gastric emptying in functional dyspepsia显示文摘 | Liebregts T Adam B Bredack C | 2011 | Am J Gastroenterol2011，106，6： | 1 |
| 11 | Distribution and identity of biotypes of Bemisia tabaci (Gennadius) (Hemiptera:Aleyrodidae) in member countries of the secretariat of the Pacific community显示文摘 | De Barro P J Liebregts W Carver M | 1998 | Australian Journal of Entomology1998，37，3： | 1 |
| 12 | A placebo-controlled trial of itopride in functional dyspepsia显示文摘 | Holtmann G Talley NJ Liebregts T | 2006 | N Engl J Med2006，354，8： | 1 |
| 13 | Immune activation in patients with irritable bowel syndrome 显示文摘 | Liebregts T Adam B Bredack C | 2007 | Gastroenterology2007，132，： | 1 |
| 14 | Severity of mucosal inflanmmation as a predictor for alterations of visceral sensory function in a rat model显示文摘 | Adam B Liebregts T Gschosmann JM | 2006 | Pain2006，123，12： | 1 |
| 15 | Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model显示文摘 | Adam B Liebregts T Gschossmann M | 2006 | Pain2006，123，12： | 1 |
| 16 | Hyperthermia induces agedependent changes in rat hippocampal excitability显示文摘 | Liebregts MT McLachlan RS Leung LS | 2002 | Ann Neurol2002，52，3： | 1 |
| 17 | 伊托必利治疗功能性消化不良:一项安慰剂对照试验显示文摘BACKGROUND:The treatment of patients with functional dyspepsia remains unsatisfactory.We assessed the efficacy of itopride,a dopamine D2 antagonist with acetylcholinesterase effects,in patients with functional dyspepsia.METHODS:Patients with functional dyspepsia were randomly assigned to receive either itopride(50,100,or 200 mg three times daily)or placebo.After eight weeks of treatment,three primary efficacy end points were analyzed:the change from baseline in the severity of symptoms of functional dyspepsia(as assessed by the Leeds Dyspepsia Questionnaire),patients’global assessment of efficacy(the proportion of patients without symptoms or with marked improvement),and the severity of pain or fullness as rated on a five-grade scale.RESULTS:We randomly assigned 554 patients;523 had outcome data and could be included in the analyses.After eight weeks,41 percent of the patients receiving placebo were symptom-free or had marked improvement,as compared with 57 percent,59 percent,and 64 percent receiving itopride at a dose of 50,100,or 200 mg three times daily,respectively(P < 0.05 for all comparisons between placebo and itopride).Although the symptom score improved significantly in all four groups,an overall analysis revealed that itopride was significantly superior to placebo,with the greatest symptom-score improvement in the 100 and 200 mg groups(-6.24 and-6.27,vs.-4.50 in the placebo group;P = 0.05).Analysis of the combined end point of pain and fullness showed that itopride yielded a greater rate of response than placebo(73 percent vs.63 percent,P = 0.04).CONCLUSIONS:Itopride significantly improves symptoms in patients with functional dyspepsia. | Holtmann G. Talley N.J. Liebregts T. 王晓君 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，9： | 1 |
| 18 | A placebo-controlled trial of itopride in functional dyspepsia显示文摘 | Holtmann G Tally NJ Liebregts T | 2006 | N Engl J Med2006，354，8： | 1 |
| 19 | Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine 显示文摘 | Adam B Liebregts T Holtmann G | 2006 | Z Gastroenterol2006，44，： | 1 |
| 20 | Immune activation in patients with irritable bowel syndrome 显示文摘 | Liebregts T Adam B Bredack C | 2007 | Gastroenterology2007，132，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员